FDA Approval of Desmopressin for Nocturia

• Autores: Michael Fralick, Aaron S. Kesselheim
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 317, Nº. 20, 2017, págs. 2059-2060
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • On March 3, 2017, the US Food and Drug Administration (FDA) approved desmopressin nasal spray (Noctiva) for the “treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.”1 According to the product manufacturer, Serenity Pharmaceuticals, nocturia is a common condition affecting “over 89 million adults in the U.S.”